Recovery ⏱ Half-life: Short. Experimental

Livagen

Livagen (KEAW Peptide)

Updated March 15, 2026

Evidence at a Glance

Regulatory statusExperimental
Khavinson short-peptide bioregulator (Lys-Glu-Asp-Ala); not an approved drug in the US; sold for research/supplement use only.
Human evidenceNone
Animal evidenceLimited

Livagen is a synthetic tetrapeptide bioregulator whose evidence is confined to Russian ex-vivo cell and limited animal studies with no controlled clinical trials.

What the research does not support

  • It has no completed randomized human clinical trials demonstrating liver, immune, or anti-aging benefit.
  • Its 'chromatin decondensation' findings come from lab-dish lymphocyte experiments, not proven outcomes in people.
  • It is not approved by any Western regulator, and its claimed liver tissue-specificity is an extrapolation, not directly demonstrated.
  • Independent replication of the St. Petersburg group's results outside Russia is largely absent.
Half-Life
Short.
Mol. Weight
~489 g/mol

What is Livagen?

Livagen is a synthetic peptide bioregulator designed to support liver tissue function and hepatocyte recovery.

Research Applications

Hepatoprotection, liver recovery, toxin damage models, and hepatocyte function research.

Dosage Information (Research Use)

10-20 mg/day for 10-30 day courses. Research use only.

Reconstitution & Handling

Standard.

Half-Life & Pharmacokinetics

Short.

Reported Observations in Literature

Generally well-tolerated.

Key Research References

  • Khavinson VK. “Peptide Bioregulators.” 2003

How Livagen Works

Livagen targets hepatocyte gene expression, supporting liver cell resilience and recovery from toxic or inflammatory insult.

Research Findings

Studied in liver damage models and hepatoprotection research.

Dosage & Administration

10-20 mg/day for 10-30 day courses. Research use only.

Safety & Side Effects

Generally well-tolerated.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Lys-Glu-Ala-Trp
Molecular Weight ~489 g/mol
Half-Life Short.
Available Sizes 5mg
Storage Lyophilized: -20°C.

Key Research References

  • Khavinson VK. "Peptide Bioregulators." 2003

Related Peptides

View all →
Cardiogen
Recovery
Short peptide bioregulator studied for cardiac tissue support, anti-fibrotic activity, and myocardial remodeling.
View Profile →
Linaclotide
Recovery
FDA-approved 14-amino acid peptide for IBS-C and chronic constipation that works by activating guanylate cyclase-C receptors in the…
View Profile →
Vesugen
Recovery
Vascular-targeting tripeptide bioregulator researched for endothelial function and microcirculation support.
View Profile →